JessicaHawleyMD(She/Her)

Oncology • Seattle, WA

Genitourinary Oncology

Physician

Join to view full profile

Dr. Hawley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hawley's full profile

Already have an account?

Office
825 Eastlake Ave E
Seattle, WA 98109
Phone+1 206-606-2284

Fax+1 206-606-6414

Education & Training

Mailman School of Public Health at Columbia UniversityMS, Biostatistics (Patient-Oriented Reaearch), 2020 - 2022
New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 2017 - 2020
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2011 - 2014
University of Wisconsin School of Medicine & Public HealthClass of 2011

Certifications & Licensure

CA State Medical License 2015 - Present
WA State Medical License 2021 - 2026
NY State Medical License 2017 - 2022
MA State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

4 citations
The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.
Jean Hoffman-Censits, Petros Grivas, Thomas Powles, Jessica Hawley, Karin Tyroller
Future Oncology. 2024-02-01
36 citations
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer.
Julie Fu, Sonya A Reid, Benjamin French, Cassandra Hennessy, Clara Hwang
JAMA Network Open. 2022-03-01
1212 citations
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein
Lancet. 2020-06-20

Lectures

Correlation between innate cytokine levels and progression in men with biochemically recurrent prostate cancer treated with intermittent hormonal therapy.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Assessing Regional Differences in COVID-19 Outcomes Among Patients with CancerJanuary 4th, 2022
The Prostate Cancer Foundation Announces 2020 Young Investigator Awards Totaling $6 Million for Prostate Cancer ResearchDecember 16th, 2020
A COVID-19-Cancer InterplayOctober 7th, 2020
Join now to see all

Professional Memberships